U-Needle is proud to announce it has recently joined forces with Inreda Diabetic and the University of Twente to develop the world's first Microneedle Artificial Pancreas (MAP).
In the MAP project the advanced AP technology of Inreda Diabetic, the intradermal administration technology of U-Needle and the sensor expertise of the University of Twente are brought together. The project aims to administer insulin and glucagon much faster than currently used Continuous Subcutaneous Insulin Infusion (CSII) systems, reducing postprandial peaks and obtaining an improved time-in-range. In order to do this, the commonly used subcutaneous infusion set that gives a relatively slow uptake will be replaced with a much faster intradermal infusion set, creating a new Continuous Intradermal Insulin (and Glucagon) Infusion system. It is believed this will eliminate the need for manual glucose management, even during meals.
Intradermal infusion as well as the use of Glucagon (next to Insulin) in AP systems have the potential to become tomorrows new standard. The Microneedle Artificial Pancreas as developed in the project is expected to provide a significant increase in quality of life for millions of people living with diabetes.
Execution of the ambitious MAP project involves an investment of 3 million Euro jointly funded by the consortium partners and co-funder The European Commission through (EFRO | OP Oost).
Please visite our website for further information about U-Needle.